Natixis’s Pacira BioSciences PCRX Stock Holding History

Natixis’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$768K	Hold	34,000	–	–	﹤0.01%	737
2025 Q4	$880K	Sell	34,000 -89,900	-73%	-$2.14M	﹤0.01%	746
2025 Q3	$3.19M	Sell	123,900 -27,400	-18%	-$673K	0.01%	509
2025 Q2	$3.62M	Buy	151,300 +151,250	+302,500%	+$3.81M	0.02%	399
2025 Q1	$1.24K	Sell	50 -92,200	-100%	-$2.21M	﹤0.01%	928
2024 Q4	$1.74M	Buy	+92,250	New	+$1.62M	0.01%	494
2024 Q3	–	Sell	-118,250	Closed	-$3.38M	–	1078
2024 Q2	$3.38M	Buy	118,250 +115,000	+3,538%	+$3.27M	0.02%	338
2024 Q1	$95K	Buy	+3,250	New	+$99.8K	﹤0.01%	782
2023 Q4	–	Sell	-21,500	Closed	-$660K	–	1141
2023 Q3	$660K	Buy	21,500 +6,000	+39%	+$216K	0.01%	565
2023 Q2	$621K	Sell	15,500 -13,000	-46%	-$537K	0.01%	613
2023 Q1	$1.16M	Buy	+28,500	New	+$1.13M	0.01%	499
2022 Q4	–	Sell	-25,250	Closed	-$1.34M	–	1290
2022 Q3	$1.34M	Buy	+25,250	New	+$1.4M	0.01%	698

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's PCRX Position: Q1 2026 in Review

Natixis held its Pacira BioSciences (PCRX) position steady in Q1 2026 at 34,000 shares worth $768K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Natixis first reported a position in PCRX in Q3 2022 and has held it in 12 quarters since. The position peaked at $3.62M in Q2 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Natixis held 34,000 shares of Pacira BioSciences worth $768K as of Q1 2026.
Natixis left its Pacira BioSciences share count unchanged in Q1 2026.
Pacira BioSciences made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #737 holding.
Natixis first reported a position in Pacira BioSciences in Q3 2022 and has held it in 12 quarters since.
Natixis's Pacira BioSciences position peaked at $3.62M in Q2 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.